Breaking News, Financial News

Catalent Revenues up 4% in the Quarter

Biologics revenue up 3% and Pharma and Consumer Health revenue up 5%.

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent
1Q Revenues: $1.02 billion (+4%)
1Q Loss: $129 million (loss of $759 million Fiscal 1Q24)
Comments: Biologics revenue was $461 million in the quarter, up 3%. Pharma and Consumer Health revenues were $563, up 5%. After excluding COVID-related revenue of approximately $30 million in the first quarter of fiscal 2025 and approximately $100 million in first quarter of fiscal 2024, net revenue increased 13%.
 
The merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction for $16.5 billion, is expected to close at end of 2024, subject to customary closing conditions.

Related News: Catalent Issues Letter Regarding Pending Acquisition by Novo Holdings

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters